NBE Therapeutics
Ina Hellmann has had a long and varied career in the field of biochemistry and related sciences. From 2006 to 2012, they worked in a variety of roles. Ina began as a Research Assistant I in the Laboratory of Welkin E. Johnson at Harvard Medical School and New England Primate Research Center in 2006. Ina then completed a Master's thesis in the Laboratory of Dirk Lindemann at TU Dresden, Institute of Virology in 2006. In 2007, they became a Research Assistant II in the Laboratory of Normal L. Letvin at Harvard Medical School and Beth Israel Deaconess Medical Center. From 2009 to 2012, they were a Ph.D candidate in the same laboratory. In 2012, they became a Post-doctoral Researcher in the Laboratory of Sai T. Reddy at ETH Zürich in the Department of Biosystems Science and Engineering. Finally, they were hired as a Program Manager Early Development and Laboratory head for pre-clinical ADC development at NBE-Therapeutics AG in 2012. In 2016, they were promoted to Ph.D Scientist II.
Ina Hellmann received their Bachelor of Science in Biology from Technische Universität Dresden in 2001-2003. Ina then went on to receive their Master of Science in Biology from the same university in 2001-2006. Lastly, they completed their Ph.D in Immunology/Viral Pathogenesis from Harvard Medical School in 2009-2012.
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.